Share Email Print
cover

Proceedings Paper

Review of technology development and clinical trials of transcranial laser therapy for acute ischemic stroke treatment
Author(s): Brian E. Catanzaro; Jackson Streeter; Luis de Taboada
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Stroke is the one of the leading causes of mortality in the United States, claiming 600,000 lives each year. Evidence suggests that near infrared (NIR) illumination has a beneficial effect on a variety of cells when these cells are exposed to adverse conditions. Among these conditions is the hypoxic state produced by acute ischemic stroke (AIS). To demonstrate the impact NIR Transcranial Laser Therapy (TLT) has on AIS in humans, a series of double blind, placebo controlled clinical trials were designed using the NeuroThera(R) System (NTS). The NTS was designed and developed to treat subjects non-invasively using 808 nm NIR illumination. TLT, as it applies to stroke therapy, and the NTS will be described. The results of the two clinical trials: NeuroThera(R) Safety and Efficacy Trial 1 (NEST-1) and NeuroThera(R) Safety and Efficacy Trial 2 (NEST-2) will be reviewed and discussed.

Paper Details

Date Published: 26 February 2010
PDF: 7 pages
Proc. SPIE 7552, Mechanisms for Low-Light Therapy V, 75520J (26 February 2010); doi: 10.1117/12.842043
Show Author Affiliations
Brian E. Catanzaro, CFE Services (United States)
Jackson Streeter, Banyon Biomarkers (United States)
Luis de Taboada, PhotoThera, Inc. (United States)


Published in SPIE Proceedings Vol. 7552:
Mechanisms for Low-Light Therapy V
Michael R. Hamblin; Ronald W. Waynant; Juanita Anders, Editor(s)

© SPIE. Terms of Use
Back to Top